New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
10:00 EDTITCI, WCIC, INCY, TRVN, COV, RTEC, LJPC, HELI, GOLD, KLIC, EPE, NUTR, IVAC, APLOn The Fly: Analyst Initiation Summary
Atlas Pipeline Partners (APL) initiated with a Hold at Deutsche Bank... CHC Group (HELI) initiated with a Buy at UBS... EP Energy (EPE) initiated with an Overweight at JPMorgan... Intevac (IVAC) initiated with a Neutral at B. Riley... Kulicke & Soffa (KLIC) initiated with a Buy at B. Riley... La Jolla Pharmaceutical (LJPC) initiated with an Outperform at Wedbush... Nutraceutical (NUTR) initiated with an Outperform at Imperial Capital... Randgold Resources (GOLD) initiated with a Buy at UBS... Rudolph Technologies (RTEC) initiated with a Buy at B. Riley... Trevena (TRVN) initiated with an Outperform at JMP Securities... WCI Communities (WCIC) reinstated with an Outperform at Credit Suisse... Covidien (COV) initiated with a Buy at CRT Capital... Incyte (INCY) coverage assumed with a Buy at BofA/Merrill... Intra-Cellular (ITCI) initiated with an Outperform at Cowen.
News For APL;EPE;HELI;IVAC;KLIC;LJPC;NUTR;GOLD;RTEC;TRVN;WCIC;COV;INCY;ITCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 20, 2014
07:04 EDTNUTRNutraceutical reports Q4 EPS 35c with charges, one estimate 40c
Subscribe for More Information
05:14 EDTCOVCovidien achieves CE Mark for Nellcor Bedside SpO2 Patient Monitoring System
Subscribe for More Information
November 19, 2014
08:15 EDTCOVMedtronic reported solid Q2 results, says Bernstein
Bernstein notes that Medtronic's (MDT) sales growth accelerated to 5%, and the firm thinks the company's market share of the ICD market is poised to increase next quarter. Bernstein views Medtronic as "a strong buy" into the close of its acquisition of Covidien (COV). The firm reiterates an Outperform rating on Medtronic.
06:54 EDTCOVMedtronic reiterated as a top pick at JPMorgan
Subscribe for More Information
November 18, 2014
15:18 EDTRTECRudolph Technologies approves restructuring, sees cutting headcount 4%
Subscribe for More Information
12:08 EDTCOVOn The Fly: Midday Wrap
Subscribe for More Information
09:08 EDTCOVMedtronic says regulatory processes for Covidien deal 'all on track'
Subscribe for More Information
07:32 EDTTRVNTrevena price target raised to $21 from $18 at JMP Securities
Subscribe for More Information
07:20 EDTCOVMedtronic confirms commitment to Covidien transaction
Subscribe for More Information
November 17, 2014
16:04 EDTTRVNTrevena reports TRV130 Phase 2a/b Study achieved primary endpoint
Subscribe for More Information
11:06 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:01 EDTRTECRudolph Technologies receives multi-system orders for MetaPULSE G
Subscribe for More Information
November 14, 2014
17:27 EDTCOVPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
12:43 EDTCOVMedtronic readying $10B bond sale for Covidien deal, WSJ reports
Subscribe for More Information
11:50 EDTCOVMedtronic readying $10B bond sale for Covidien deal, Dow reports
Subscribe for More Information
November 13, 2014
18:07 EDTCOVCovidien' VenaSeal closure system shows positive results
Covidien announced the six-month results of the VeClose pivotal study of the safety and effectiveness of the VenaSeal closure system in patients with chronic venous insufficiency having symptomatic reflux in the great saphenous vein. The VeClose randomized controlled non-inferiority study compared the safety and effectiveness of the VenaSeal system to that of the ClosureFast endovenous radiofrequency ablation catheter. Covidien's ClosureFast catheter is an endovenous radiofrequency ablation catheter designed to collapse and close enlarged leg veins. The VenaSeal system is not approved and currently limited to investigational use in the U.S. At three months, the complete closure of the great saphenous veins achieved in more than 98.9% of patients treated with the VenaSeal system compared to 95.6% of patients treated with the ClosureFast catheter. The closure rate at six months was 98.9% and 94.3%.
13:32 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:27 EDTCOVMedtronic likely to continue to make new highs, Barron's says
Subscribe for More Information
13:26 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use